Better Buy: Biogen vs. Celgene

Better Buy: Biogen vs. Celgene

Fool

Image source: Flickr.

Fresh off a strong Q2 earnings beat and riding high on takeout rumors, the past 3 months have been good to Biogen (NASDAQ: BIIB) investors, with shares up 27% since July. The same, however, cannot be said for Celgene (NASDAQ: CELG), up a measly 3% and trailing the iShares Biotech Index (NASDAQ: IBB).

Continue reading

view Fool